0
By clicking the button, I accept the Terms of Use of the service and its Privacy Policy, as well as consent to the processing of personal data.
Don’t have an account? Signup
Powered by :
The company's exceptional items for the fourth quarter of 2021-22 stood at Rs 3,935.75 crore against Rs 672.81 crore in the corresponding quarter of 2020-21. Exceptional items include settlements, and provisions related to Taro Pharmaceuticals, and Ranbaxy.
Share this article
If you liked this article share it with your friends.they will thank you later